Delving into the Latest Updates on 上海贝斯昂科生物科技有限公司 with Synapse

An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the safety and efficacy of NK520 in the treatment of pediatric relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

开始日期2024-07-01

申办/合作机构

上海贝斯昂科生物科技有限公司

[+1]

NCT06541444

/ Recruiting早期临床1期

An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

开始日期2024-07-01

申办/合作机构

上海贝斯昂科生物科技有限公司

[+1]

NCT06098898

/ Enrolling by invitation早期临床1期

Exploratory Study of NK510 Cell Therapy Combined With Monoclonal Antibody in the Treatment of Recurrent and Refractory Advanced Gastric Cancer

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.

开始日期2023-11-01

申办/合作机构

上海贝斯昂科生物科技有限公司

100 项与上海贝斯昂科生物科技有限公司相关的临床结果

登录后查看更多信息

0 项与上海贝斯昂科生物科技有限公司相关的专利（医药）

登录后查看更多信息

100 项与上海贝斯昂科生物科技有限公司相关的药物交易

登录后查看更多信息

100 项与上海贝斯昂科生物科技有限公司相关的转化医学

登录后查看更多信息